Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD

Journal of the American Society of Nephrology

Volumn 26, Issue 10, 2015, Pages 2328-2339

  Isakova, Tamara ^a   Ix, Joachim H ^b   Sprague, Stuart M ^c   Raphael, Kalani L ^d   Fried, Linda ^e   Gassman, Jennifer J ^f   Raj, Dominic ^g   Cheung, Alfred K ^d   Kusek, John W ^h   Flessner, Michael F ^h   Wolf, Myles ^a   Block, Geoffrey A ⁱ  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g GEORGE WASHINGTON UNIVERSITY   (United States)

^h NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

ⁱ Denver Nephrology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; NICOTINAMIDE; NICOTINIC ACID; PHOSPHATE; PHOSPHATE BINDING AGENT; FIBROBLAST GROWTH FACTOR;

ADVERSE OUTCOME; ARTERY CALCIFICATION; BONE METABOLISM; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; END STAGE RENAL DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; META ANALYSIS; MINERAL METABOLISM; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PHOSPHATE BLOOD LEVEL; PHOSPHATE INTAKE; PHOSPHATE URINE LEVEL; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; URINARY EXCRETION; ANTAGONISTS AND INHIBITORS; METABOLISM; RENAL INSUFFICIENCY, CHRONIC;

FIBROBLAST GROWTH FACTORS; HUMANS; PHOSPHATES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84942867397     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2015020117     Document Type: Review

References (102)

1. Weiner DE, Seliger SL: Cognitive and physical function in chronic kidney disease. Curr Opin Nephrol Hypertens 23: 291-297, 2014.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296- 1305, 2004.
3. Honeycutt AA, Segel JE, Zhuo X, Hoerger TJ, Imai K, Williams D: Medical costs of CKD in the Medicare population. J Am Soc Nephrol 24: 1478-1483, 2013.
4. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD; The Collaborative Study Group: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.N Engl J Med 329: 1456-1462, 1993.
5. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, HerringtonW, MafhamM, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377: 2181- 2192, 2011.
6. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J: Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 305: 2532-2539, 2011.
7. Levin A, Djurdjev O, Beaulieu M, Er L: Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. Am J Kidney Dis 52: 661-671, 2008.
8. Landray MJ, Emberson JR, Blackwell L, Dasgupta T, Zakeri R, Morgan MD, FerroCJ, Vickery S, Ayrton P, Nair D, Dalton RN, Lamb EJ, Baigent C, Townend JN, Wheeler DC: Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study. Am J Kidney Dis 56: 1082- 1094, 2010.
9. Nickolas TL, McMahon DJ, Shane E: Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am SocNephrol 17: 3223- 3232, 2006.
10. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR; UKPDS GROUP: Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63: 225-232, 2003.
11. Dalrymple LS, Katz R, Kestenbaum B, Shlipak MG, Sarnak MJ, Stehman-Breen C, Seliger S, Siscovick D, Newman AB, Fried L: Chronic kidney disease and the risk of endstage renal disease versus death. J Gen Intern Med 26: 379-385, 2011.
12. Kidney DiseaseImproving Global Outcomes (KDIGO) CKD Work Group: KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 3: S1- S150, 2013.
13. Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79: 1370- 1378, 2011.
14. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: Serum phosphate levels andmortality risk among people with chronic kidney disease. J Am Soc Nephrol 16: 520- 528, 2005.
15. Norris KC, Greene T, Kopple J, Lea J, Lewis J, Lipkowitz M, Miller P, Richardson A, Rostand S, Wang X, Appel LJ: Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease. J AmSoc Nephrol 17: 2928-2936, 2006.
16. Adeney KL, Siscovick DS, Ix JH, Seliger SL, Shlipak MG, Jenny NS, Kestenbaum BR: Association of serum phosphate with vascular and valvular calcification in moderate CKD. J AmSocNephrol 20: 381-387, 2009.
17. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M; HOST Investigators: FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 22: 1913-1922, 2011.
18. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Group: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305: 2432-2439, 2011.
19. Scialla JJ, Astor BC, Isakova T, Xie H, Appel LJ, Wolf M: Mineral metabolites and CKD progression in African Americans. J Am Soc Nephrol 24: 125-135, 2013.
20. Scialla JJ, Lau WL, Reilly MP, Isakova T, Yang HY, Crouthamel MH, Chavkin NW, Rahman M, Wahl P, Amaral AP, Hamano T, Master SR, Nessel L, Chai B, Xie D, Kallem RR, Chen J, Lash JP, Kusek JW, Budoff MJ, Giachelli CM, Wolf M; Chronic Renal Insufficiency Cohort Study Investigators: Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int 83: 1159-1168, 2013.
21. Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, Ojo A, Zhang X, Nessel L, Hamano T, Grunwald JE, Raj DS, Yang W, He J, Lash JP, Go AS, Kusek JW, Feldman H, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators: Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol 25: 349- 360, 2014.
22. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87: E10- E17, 2000.
23. FaulC, Amaral AP, Oskouei B, HuMC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, FischerM, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, MoeOW, Kuro-OM, Kusek JW, KeaneMG, Wolf M: FGF23 induces left ventricular hypertrophy. J Clin Invest 121: 4393-4408, 2011.
24. Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, Strippoli GF: Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 305: 1119-1127, 2011.
25. Kovesdy CP, Kuchmak O, Lu JL, Kalantar- Zadeh K: Outcomes associated with phosphorus binders in menwith non-dialysis-dependent CKD. Am J Kidney Dis 56: 842-851, 2010.
26. Scialla JJ, Wolf M: Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nat Rev Nephrol 10: 268-278, 2014.
27. National Kidney Foundation: K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 42[Suppl 3]: S1- S201, 2003.
28. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 113: S1-S130, 2009.
29. Moe SM, Zidehsarai MP, Chambers MA, Jackman LA, Radcliffe JS, Trevino LL, Donahue SE, Asplin JR: Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol 6: 257-264, 2011.
30. Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moysés RM: Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 5: 286-291, 2010.
31. Isakova T, Barchi-Chung A, Enfield G, Smith K, Vargas G, Houston J, Xie H, Wahl P, Schiavenato E, Dosch A, Gutiérrez OM, Diego J, Lenz O, Contreras G, Mendez A, Weiner RB, Wolf M: Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD. Clin J AmSoc Nephrol 8: 1009-1018, 2013.
32. Ix JH, Ganjoo P, Tipping D, Tershakovec AM, Bostom AG: Sustained hypophosphatemic effect of once-daily niacin/laropiprant in dyslipidemic CKD stage 3 patients. Am J Kidney Dis 57: 963-965, 2011.
33. Antoniucci DM, Yamashita T, Portale AA: Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 91: 3144-3149, 2006.
34. Burnett SM, Gunawardene SC, Bringhurst FR, Jüppner H, Lee H, Finkelstein JS: Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 21: 1187-1196, 2006.
35. Ferrari SL, Bonjour J-P, Rizzoli R: Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90: 1519-1524, 2005.
36. Dominguez JH, Gray RW, Lemann J Jr: Dietary phosphate deprivation in women and men: effects on mineral and acid balances, parathyroid hormone and the metabolism of 25-OH-vitamin D. J Clin Endocrinol Metab 43: 1056-1068, 1976.
37. Portale AA, Halloran BP, Murphy MM, Morris RC Jr: Oral intake of phosphorus can determine the serumconcentration of 1, 25- dihydroxyvitamin D by determining its production rate in humans. J Clin Invest 77: 7-12, 1986.
38. Radanovic T, Wagner CA, Murer H, Biber J: Regulation of intestinal phosphate transport. I. Segmental expression and adaptation to low-P(i) diet of the type IIb Na(+)-P(i) cotransporter in mouse small intestine. Am J Physiol Gastrointest Liver Physiol 288: G496-G500, 2005.
39. Schiavi SC, Tang W, Bracken C, O'Brien SP, SongW, Boulanger J, Ryan S, Phillips L, Liu S, Arbeeny C, Ledbetter S, Sabbagh Y: Npt2b deletion attenuates hyperphosphatemia associated with CKD. J Am Soc Nephrol 23: 1691-1700, 2012.
40. Ramirez JA, Emmett M, White MG, Fathi N, Santa Ana CA, Morawski SG, Fordtran JS: The absorption of dietary phosphorus and calcium in hemodialysis patients. Kidney Int 30: 753-759, 1986.
41. Hruska KA, Mathew S, Lund R, Qiu P, Pratt R: Hyperphosphatemia of chronic kidney disease. Kidney Int 74: 148-157, 2008.
42. Isakova T, Gutiérrez OM, Smith K, Epstein M, Keating LK, Jüppner H, Wolf M: Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease.Nephrol Dial Transplant 26: 584-591, 2011.
43. Sprague SM, Abboud H, Qiu P, Dauphin M, Zhang P, Finn W: Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol 4: 178-185, 2009.
44. Russo D, Miranda I, Ruocco C, Battaglia Y, Buonanno E, Manzi S, Russo L, Scafarto A, Andreucci VE: The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 72: 1255-1261, 2007.
45. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, Kooienga L, Thadhani R, Mannstadt M, Wolf M, Chertow GM: Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 23: 1407-1415, 2012.
46. Chue CD, Edwards NC, Moody WE, Steeds RP, Townend JN, Ferro CJ: Serum phosphate is associatedwith left ventricular mass in patients with chronic kidney disease: a cardiac magnetic resonance study. Heart 98: 219-224, 2012.
47. Seifert ME, de las Fuentes L, Rothstein M, Dietzen DJ, Bierhals AJ, Cheng SC, RossW, Windus D, Dávila-Román VG, Hruska KA: Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease. Am J Nephrol 38: 158-167, 2013.
48. Portale AA, Halloran BP, Morris RC Jr: Dietary intake of phosphorus modulates the circadian rhythm in serum concentration of phosphorus. Implications for the renal production of 1, 25-dihydroxyvitamin D. J Clin Invest 80: 1147-1154, 1987.
49. Ix JH, Anderson CA, Smits G, Persky MS, Block GA: Effect of dietary phosphate intake on the circadian rhythm of serum phosphate concentrations in chronic kidney disease: a crossover study. Am J Clin Nutr 100: 1392-1397, 2014.
50. Calvo MS, Kumar R, Heath H 3rd: Elevated secretion and action of serum parathyroid hormone in young adults consuming high phosphorus, low calcium diets assembled fromcommon foods. J Clin Endocrinol Metab 66: 823-829, 1988.
51. Isakova T, Xie H, Barchi-Chung A, Smith K, Sowden N, EpsteinM, Collerone G, Keating L, Jüppner H, Wolf M: Daily variability in mineral metabolites in CKD and effects of dietary calcium and calcitriol. Clin J Am Soc Nephrol 7: 820-828, 2012.
52. Isakova T, Gutierrez O, Shah A, Castaldo L, Holmes J, Lee H, Wolf M: Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol 19: 615-623, 2008.
53. Isakova T, Xie H, Barchi-Chung A, Vargas G, Sowden N, Houston J, Wahl P, Lundquist A, Epstein M, Smith K, Contreras G, Ortega L, Lenz O, Briones P, Egbert P, Ikizler TA, Jueppner H, Wolf M: Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. Clin J Am Soc Nephrol 6: 2688- 2695, 2011.
54. Khosla N, Fettman S, Gerseny H, Sprague SM: Impact of lanthanum carbonate on FGF23 in chronic kidney disease stages 3-5. [Abstract] J Am Soc Nephrol 23: 312A, 2012.
55. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Mallamaci F, Zoccali C: Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. Am J Kidney Dis 59: 177-185, 2012.
56. Vlassara H, Uribarri J, Cai W, Goodman S, Pyzik R, Post J, Grosjean F, Woodward M, Striker GE: Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol 7: 934-942, 2012.
57. Block GA, Fishbane S, Rodriguez M, Smits G, Shemesh S, Pergola PE, WolfM, Chertow GM: A 12-week, double-blind, placebocontrolled trial of ferric citrate for the treatment of irondeficiency anemia and reduction of serum phosphate in patients with CKD stages 3-5. Am J Kidney Dis 65: 728-736, 2014.
58. Di Iorio B, Di Micco L, Torraca S, Sirico ML, Russo L, Pota A, Mirenghi F, Russo D: Acute effects of very-low-protein diet on FGF23 levels: a randomized study. Clin J Am Soc Nephrol 7: 581-587, 2012.
59. Sigrist M, Tang M, Beaulieu M, Espino- Hernandez G, Er L, Djurdjev O, Levin A: Responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD): results of a randomized trial. Nephrol Dial Transplant 28: 161-169, 2013.
60. Rao M, Steffes M, Bostom A, Ix JH: Effect of niacin on FGF23 concentration in chronic kidney disease. Am J Nephrol 39: 484-490, 2014.
61. Reilly AM, Gray AK, Moe SM, Ichikawa S: Nicotinamide treatment in a murine model of familial tumoral calcinosis reduces serum Fgf23 and raises heart calcium. Bone 67: 139-144, 2014.
62. Sabbagh Y, O'Brien SP, Song W, Boulanger JH, Stockmann A, Arbeeny C, Schiavi SC: Intestinal npt2b plays a major role in phosphate absorption and homeostasis. J Am Soc Nephrol 20: 2348-2358, 2009.
63. Daugirdas JT, FinnWF, EmmettM, Chertow GM; Frequent Hemodialysis Network Trial Group: The phosphate binder equivalent dose. Semin Dial 24: 41-49, 2011.
64. Tonelli M, Pannu N, Manns B: Oral phosphate binders in patients with kidney failure. N Engl J Med 362: 1312-1324, 2010.
65. Burke SK, Slatopolsky EA, Goldberg DI: RenaGel, a novel calcium- And aluminiumfree phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant 12: 1640-1644, 1997.
66. Pennick M, Poole L, Dennis K, Smyth M: Lanthanum carbonate reduces urine phosphorus excretion: evidence of high-capacity phosphate binding. Ren Fail 34: 263-270, 2012.
67. Hill KM, Martin BR, Wastney ME, McCabe GP, Moe SM, Weaver CM, Peacock M: Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int 83: 959-966, 2013.
68. Shimada T, Yamazaki Y, Takahashi M, Hasegawa H, Urakawa I, Oshima T, Ono K, Kakitani M, Tomizuka K, Fujita T, Fukumoto S, Yamashita T: VitaminDreceptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 289: F1088-F1095, 2005.
69. Rodriguez-Ortiz ME, Lopez I, Muñoz- Castañeda JR, Martinez-Moreno JM, Ramírez AP, Pineda C, Canalejo A, Jaeger P, Aguilera- Tejero E, Rodriguez M, Felsenfeld A, Almaden Y: Calcium deficiency reduces circulating levels of FGF23. J Am Soc Nephrol 23: 1190-1197, 2012.
70. Giral H, Caldas Y, Sutherland E, Wilson P, Breusegem S, Barry N, Blaine J, Jiang T, Wang XX, Levi M: Regulation of rat intestinal Na-dependent phosphate transporters by dietary phosphate. Am J Physiol Renal Physiol 297: F1466-F1475, 2009.
71. Marks J, Churchill LJ, Srai SK, Biber J, Murer H, Jaeger P, Debnam ES, Unwin RJ, Epithelial T; Epithelial Transport and Cell Biology Group: Intestinal phosphate absorption in a model of chronic renal failure. Kidney Int 72: 166-173, 2007.
72. Katai K, Tanaka H, Tatsumi S, Fukunaga Y, Genjida K, Morita K, Kuboyama N, Suzuki T, Akiba T, Miyamoto K, Takeda E: Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine. Nephrol Dial Transplant 14: 1195- 1201, 1999.
73. Kuboyama N, Watanabe Y, Yamaguchi M, Sato K, Suzuki T, Akiba T: Effects of niceritrol on faecal and urinary phosphate excretion in normal rats. Nephrol Dial Transplant 14: 610-614, 1999.
74. Cheng SC, YoungDO, Huang Y, Delmez JA, Coyne DW: A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 3: 1131- 1138, 2008.
75. ShahbazianH, ZafarMohtashami A, Ghorbani A, Abbaspour MR, Belladi Musavi SS, Hayati F, Lashkarara GR: Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial. Nefrologia 31: 58-65, 2011.
76. Takahashi Y, Tanaka A, Nakamura T, Fukuwatari T, Shibata K, Shimada N, Ebihara I, Koide H: Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 65: 1099- 1104, 2004.
77. Young DO, Cheng SC, Delmez JA, Coyne DW: The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients. Perit Dial Int 29: 562-567, 2009.
78. Rosenbaum DP, Johansson S, Carlsson B, Spencer AG, Stefansson BV, Knutsson M, Jacobs JW, Charmot D: Tenapanor, a minimally absorbed NHE3 inhibitor, reduces dietary phosphorus absorption in healthy volunteers [Abstract]. J AmSocNephrol 25: 72A, 2014.
79. Labonté ED, Carreras CW, Leadbetter MR, Kozuka K, Kohler J, Koo-McCoy S, He L, Dy E, Black D, Zhong Z, Langsetmo I, Spencer AG, Bell N, Deshpande D, Navre M, Lewis JG, Jacobs JW, Charmot D:Gastrointestinal inhibition of sodium-hydrogen exchanger 3 reduces phosphorus absorption and protects against vascular calcification in CKD. J Am Soc Nephrol 26: 1138-1149, 2015.
80. Kempson SA, Colon-Otero G, Ou SY, Turner ST, Dousa TP: Possible role of nicotinamide adenine dinucleotide as an intracellular regulator of renal transport of phosphate in the rat. J Clin Invest 67: 1347- 1360, 1981.
81. Berndt TJ, Pfeifer JD, Knox FG, Kempson SA, Dousa TP: Nicotinamide restores phosphaturic effect of PTH and calcitonin in phosphate deprivation. Am J Physiol 242: F447-F452, 1982.
82. Nomura K, Tatsumi S, Miyagawa A, Shiozaki Y, Sasaki S, Kaneko I, ItoM, Kido S, SegawaH, Sano M, Fukuwatari T, Shibata K, Miyamoto K: Hepatectomy-related hypophosphatemia: a novel phosphaturic factor in the liver-kidney axis. J Am Soc Nephrol 25: 761-772, 2014.
83. Knip M, Douek IF, Moore WP, Gillmor HA, McLean AE, Bingley PJ, Gale EA; European Nicotinamide Diabetes Intervention Trial Group: Safety of high-dose nicotinamide: a review. Diabetologia 43: 1337-1345, 2000.
84. Gutiérrez OM, Wolf M: Dietary phosphorus restriction in advanced chronic kidney disease: merits, challenges, and emerging strategies. Semin Dial 23: 401-406, 2010.
85. Kalantar-Zadeh K, Gutekunst L, Mehrotra R, Kovesdy CP, Bross R, Shinaberger CS, Noori N, Hirschberg R, Benner D, Nissenson AR, Kopple JD: Understanding sources of dietary phosphorus in the treatment of patientswith chronic kidney disease. Clin J Am Soc Nephrol 5: 519-530, 2010.
86. Uribarri J, Calvo MS: Hidden sources of phosphorus in the typical American diet: does it matter in nephrology? Semin Dial 16: 186-188, 2003.
87. Moe SM, Chen NX, Seifert MF, Sinders RM, Duan D, Chen X, Liang Y, Radcliff JS, White KE, Gattone VH 2nd: A rat model of chronic kidney disease-mineral bone disorder. Kidney Int 75: 176-184, 2009.
88. Sullivan C, Sayre SS, Leon JB, Machekano R, Love TE, Porter D, Marbury M, Sehgal AR: Effect of food additives on hyperphosphatemia among patientswith end-stage renal disease: a randomized controlled trial. JAMA 301: 629-635, 2009.
89. Chue CD, Townend JN, Moody WE, ZehnderD, WallNA, Harper L, EdwardsNC, Steeds RP, Ferro CJ: Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol 24: 842-852, 2013.
90. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, Djurdjev O: Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 34: 125-134, 1999.
91. Rathi VK, Biederman RW: Expanding role of cardiovascular magnetic resonance in left and right ventricular diastolic function. Heart Fail Clin 5: 421-435, vii, 2009.
92. Shah SJ, Fonarow GC, Gheorghiade M, Lang RM. Phase II trials in heart failure: the role of cardiovascular imaging. Am Heart J 2011; 162:3-15 e3.
93. Nath KA: Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 20: 1-17, 1992.
94. Meguid El Nahas A, Bello AK: Chronic kidney disease: the global challenge. Lancet 365: 331-340, 2005.
95. Thadhani R, Pascual M, Bonventre JV: Acute renal failure.N Engl J Med 334: 1448-1460, 1996.
96. Fine LG, Norman JT: Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int 74: 867-872, 2008.
97. Fine LG, Orphanides C, Norman JT: Progressive renal disease: the chronic hypoxia hypothesis. Kidney Int Suppl 65: S74-S78, 1998.
98. Zhang JL, Morrell G, Rusinek H, Sigmund EE, Chandarana H, Lerman LO, Prasad PV, Niles D, Artz N, Fain S, Vivier PH, Cheung AK, Lee VS: New magnetic resonance imaging methods in nephrology. Kidney Int 85: 768-778, 2014.
99. Inoue T, Kozawa E, Okada H, Inukai K, Watanabe S, Kikuta T, WatanabeY, Takenaka T, Katayama S, Tanaka J, Suzuki H: Noninvasive evaluation of kidney hypoxia and fibrosis using magnetic resonance imaging. J Am Soc Nephrol 22: 1429-1434, 2011.
100. Prasad PV, Edelman RR, Epstein FH: Noninvasive evaluation of intrarenal oxygenation with BOLD MRI. Circulation 94: 3271-3275, 1996.
101. HasegawaH, Nagano N, Urakawa I, Yamazaki Y, Iijima K, Fujita T, Yamashita T, Fukumoto S, Shimada T: Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 78: 975-980, 2010.
102. Wolf M: Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 21: 1427-1435, 2010.